These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 7640345)

  • 41. Tumor necrosis factors blocking agents: analogies and differences.
    Benucci M; Saviola G; Manfredi M; Sarzi-Puttini P; Atzeni F
    Acta Biomed; 2012 Apr; 83(1):72-80. PubMed ID: 22978063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of the structure-function relationship of tumour necrosis factor. Human/mouse chimeric TNF proteins: general properties and epitope analysis.
    Tavernier J; Marmenout A; Bauden R; Hauquier G; Van Ostade X; Fiers W
    J Mol Biol; 1990 Jan; 211(2):493-501. PubMed ID: 1689779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody production by injection of living cells expressing non self antigens as cell surface type II transmembrane fusion protein.
    Nizet Y; Gillet L; Schroeder H; Lecuivre C; Louahed J; Renauld JC; Gianello P; Vanderplasschen A
    J Immunol Methods; 2011 Mar; 367(1-2):70-7. PubMed ID: 21354163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The B5 monoclonal human autoantibody binds to cell surface TNF alpha on human lymphoid cells and cell lines and appears to recognize a novel epitope.
    Boyle P; Lembach KJ; Wetzel GD
    Cell Immunol; 1993 Dec; 152(2):569-81. PubMed ID: 7504982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb.
    Liu M; Wang X; Yin C; Zhang Z; Lin Q; Zhen Y; Huang H
    Biochem J; 2007 Sep; 406(2):237-46. PubMed ID: 17472572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Determination of binding site of anti-tumour necrosis factor-alpha monoclonal antibody using hybrid and mutant proteins.
    Shingarova LN; Sagaidak LN; Berkova N; Korobko VG
    FEBS Lett; 1996 May; 386(1):72-4. PubMed ID: 8635607
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel monoclonal human IgM autoantibody which binds recombinant human and mouse tumor necrosis factor-alpha.
    Boyle P; Lembach KJ; Wetzel GD
    Cell Immunol; 1993 Dec; 152(2):556-68. PubMed ID: 7504981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tissue damage caused by TNF and complement.
    Rothstein JL; Schreiber H
    Immunol Ser; 1992; 56():453-81. PubMed ID: 1550872
    [No Abstract]   [Full Text] [Related]  

  • 49. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
    Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
    Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunobiological behaviour of rabbit precipitating and non-precipitating (co-precipitating) antibodies.
    Margni RA; Perdigón G; Abatángelo C; Gentile T; Binaghi RA
    Immunology; 1980 Nov; 41(3):681-6. PubMed ID: 7461708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock.
    Suitters AJ; Foulkes R; Opal SM; Palardy JE; Emtage JS; Rolfe M; Stephens S; Morgan A; Holt AR; Chaplin LC
    J Exp Med; 1994 Mar; 179(3):849-56. PubMed ID: 8113678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.
    Walker RE; Spooner KM; Kelly G; McCloskey RV; Woody JN; Falloon J; Baseler M; Piscitelli SC; Davey RT; Polis MA; Kovacs JA; Masur H; Lane HC
    J Infect Dis; 1996 Jul; 174(1):63-8. PubMed ID: 8656014
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.
    Chiu WC; Lai YP; Chou MY
    PLoS One; 2011 Jan; 6(1):e16373. PubMed ID: 21305012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of reactivity of monoclonal antibody (3F2) to trimeric tumor necrosis factor (TNF-alpha) with that to monomeric TNF-alpha.
    Saijo S; Watanabe N; Kobayashi Y
    J Biochem; 1995 Jul; 118(1):28-32. PubMed ID: 8537321
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of fixed cells in cell contact-dependent cytotoxicity assays for TNF: a cautionary report.
    Watts AD; Onier-Cherix N; Hunt NH; Chaudhri G
    J Immunol Methods; 1999 May; 225(1-2):179-84. PubMed ID: 10365794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumor effects of the fibroblasts transfected TNF-alpha gene and its mutants.
    Li Q; Li L; Li Z; Gong F; Feng W; Jiang X; Xiong P
    J Huazhong Univ Sci Technolog Med Sci; 2002; 22(2):92-5. PubMed ID: 12658742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.
    Knight DM; Trinh H; Le J; Siegel S; Shealy D; McDonough M; Scallon B; Moore MA; Vilcek J; Daddona P
    Mol Immunol; 1993 Nov; 30(16):1443-53. PubMed ID: 8232330
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
    Elliott MJ; Maini RN; Feldmann M; Kalden JR; Antoni C; Smolen JS; Leeb B; Breedveld FC; Macfarlane JD; Bijl H
    Lancet; 1994 Oct; 344(8930):1105-10. PubMed ID: 7934491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.